Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Background Chemotherapy

Phase 2Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Nausea

NCT07169851

Clinical

Trials by Indication[1]

Nausea1 trial

A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07169851·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Background Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Background Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Background Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

Related News